MA30433B1 - Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires - Google Patents

Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Info

Publication number
MA30433B1
MA30433B1 MA31421A MA31421A MA30433B1 MA 30433 B1 MA30433 B1 MA 30433B1 MA 31421 A MA31421 A MA 31421A MA 31421 A MA31421 A MA 31421A MA 30433 B1 MA30433 B1 MA 30433B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyrimidine derivatives
respiratory disorders
treating respiratory
disorders
Prior art date
Application number
MA31421A
Other languages
English (en)
Inventor
Ian Bruce
Judy Fox Hayler
Graham Charles Bloomfield
Lee Edwards
Brian Cox
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30433(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30433B1 publication Critical patent/MA30433B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU UN SEL OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE R1-R3 ET Y SONT DÉFINIS DANS LA DESCRIPTION, ET SON UTILISATION DANS LE TRAITEMENT DE TROUBLES DANS LESQUELS LA KINASE PI3 EST IMPLIQUÉE.
MA31421A 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires MA30433B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
MA30433B1 true MA30433B1 (fr) 2009-05-04

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31421A MA30433B1 (fr) 2006-05-23 2008-11-26 Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires

Country Status (24)

Country Link
US (5) US20090131457A1 (fr)
EP (1) EP2026811A1 (fr)
JP (1) JP2009537580A (fr)
KR (1) KR101106853B1 (fr)
CN (1) CN101443013A (fr)
AR (2) AR061057A1 (fr)
AU (1) AU2007253615B2 (fr)
BR (1) BRPI0712022A2 (fr)
CA (1) CA2650661A1 (fr)
CL (1) CL2007001455A1 (fr)
CR (1) CR10419A (fr)
EC (1) ECSP088902A (fr)
GB (1) GB0610242D0 (fr)
GT (1) GT200800256A (fr)
IL (1) IL195017A0 (fr)
MA (1) MA30433B1 (fr)
MX (1) MX2008014835A (fr)
NO (1) NO20084997L (fr)
PE (1) PE20080315A1 (fr)
RU (1) RU2008150619A (fr)
TN (1) TNSN08478A1 (fr)
TW (1) TW200806665A (fr)
WO (1) WO2007134828A1 (fr)
ZA (1) ZA200809097B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (fr) 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
WO2007114926A2 (fr) 2006-04-04 2007-10-11 The Regents Of The University Of California Antagonistes de la kinase
BRPI0813629A2 (pt) * 2007-07-26 2018-07-10 Novartis Ag derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (fr) 2008-03-14 2018-06-27 Intellikine, LLC Inhibiteurs de kinases, et procédés d utilisation associés
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (fr) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
CA2725014C (fr) 2008-05-30 2014-06-17 Amgen Inc. Inhibiteurs de la pi3 kinase
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
CA2738429C (fr) 2008-09-26 2016-10-25 Intellikine, Inc. Inhibiteurs heterocycliques de kinases
EP2358720B1 (fr) 2008-10-16 2016-03-02 The Regents of The University of California Inhibiteurs d'hétéroarylkinase à noyau fusionné
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8343961B2 (en) 2009-03-31 2013-01-01 Arqule, Inc. Substituted heterocyclic compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
WO2011047384A2 (fr) 2009-10-16 2011-04-21 The Regents Of The University Of California Procédés d'inhibition de l'activité ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CA2799579A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composes chimiques, compositions et procedes pour modulation de kinases
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (fr) 2011-09-02 2020-07-14 The Regents Of The University Of California Pyrazolo[3,4-d]pyrimidines substituees et utilisations de celles-ci
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
IN2014DN01883A (fr) 2011-09-14 2015-05-15 Proximagen Ltd
MX2014004086A (es) 2011-10-03 2014-09-22 Univ North Carolina Compuestos de pirrolopirimidina para el tratamiento del cancer.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013266438B2 (en) 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
EP2909211A4 (fr) 2012-10-17 2016-06-22 Univ North Carolina Composés pyrazolopyrimidines pour le traitement du cancer
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP2925752A4 (fr) 2012-11-27 2016-06-01 Univ North Carolina Composés à base de pyrimidine utilisables à des fins de traitement du cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US9555031B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
WO2017048702A1 (fr) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
WO2017178844A1 (fr) 2016-04-15 2017-10-19 Cancer Research Technology Limited Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase ret
SI3442535T1 (sl) 2016-04-15 2023-01-31 Cancer Research Technology Limited Heterociklične spojine kot zaviralci RET-kinaze
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
AR110922A1 (es) * 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US20230121698A1 (en) * 2019-12-23 2023-04-20 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR205234A1 (es) * 1974-05-13 1976-04-12 Lilly Co Eli Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
JP2003509428A (ja) * 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
GEP20084317B (en) * 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2003029209A2 (fr) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Composes chimiques
AU2003225933A1 (en) * 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1831225A2 (fr) * 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity

Also Published As

Publication number Publication date
CN101443013A (zh) 2009-05-27
US20140235632A1 (en) 2014-08-21
TW200806665A (en) 2008-02-01
EP2026811A1 (fr) 2009-02-25
WO2007134828A1 (fr) 2007-11-29
GT200800256A (es) 2009-05-28
CR10419A (es) 2011-07-19
US20160303132A1 (en) 2016-10-20
BRPI0712022A2 (pt) 2011-12-27
AR061057A1 (es) 2008-07-30
JP2009537580A (ja) 2009-10-29
GB0610242D0 (en) 2006-07-05
NO20084997L (no) 2008-12-22
CL2007001455A1 (es) 2008-05-16
TNSN08478A1 (en) 2010-04-14
RU2008150619A (ru) 2010-06-27
MX2008014835A (es) 2008-12-01
US20140051698A1 (en) 2014-02-20
US20090131457A1 (en) 2009-05-21
ZA200809097B (en) 2009-11-25
ECSP088902A (es) 2008-12-30
CA2650661A1 (fr) 2007-11-29
US20180125849A1 (en) 2018-05-10
AR110051A2 (es) 2019-02-20
KR20090008392A (ko) 2009-01-21
AU2007253615B2 (en) 2011-06-23
PE20080315A1 (es) 2008-06-11
KR101106853B1 (ko) 2012-01-19
AU2007253615A1 (en) 2007-11-29
US8901134B2 (en) 2014-12-02
IL195017A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
MA30433B1 (fr) Derives de pyrazolo [3,4-d] pyrimidine utilises pour traiter les troubles respiratoires
CA3087089C (fr) Composes cycliques fondus
SA521421205B1 (ar) مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
GB0112348D0 (en) Compounds
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TW200621762A (en) Novel compounds
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
WO2005063766A3 (fr) Inhibiteurs heterocycliques bicycliques des kinases p-38
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
WO2008079873A3 (fr) Utilisation de composés thiazolyle comme inhibiteurs de kinases
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
NO20091254L (no) Terapeutiske sammensetninger
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.